Minerva logo
Minerva Announces Amended Agreement for MIN-202 in Insomnia
May 31, 2017 16:05 ET | Minerva Neurosciences, Inc.
Minerva to gain global strategic control over development of MIN-202 for insomnia Janssen cash payments to Minerva of up to $70 million, including $30 million upfront All shares in Minerva held by...
bio-logo-footer.png
Blake Insomnia Therapeutics Inc. Announces Appointment of Kyle Sarwal and Ajit Johal to its Board of Directors
May 25, 2017 06:57 ET | Blake Insomnia Therapeutics, Inc.
NEW YORK, May 25, 2017 (GLOBE NEWSWIRE) -- Blake Insomnia Therapeutics Inc. (OTCQB:BKIT) a New York based pharmaceutical company is pleased to announce the appointment of Kyle Sarwal and Ajit Johal...
bio-logo-footer.png
Blake Insomnia Therapeutics and Sajo Consulting Introduce Clinical Trial Team Members
March 02, 2017 09:49 ET | Blake Insomnia Therapeutics, Inc.
NEW YORK, March 02, 2017 (GLOBE NEWSWIRE) -- Blake Insomnia Therapeutics Inc. (OTCQB:BKIT) and Sajo Consulting LLC are pleased to introduce the team appointed to conduct clinical trials of its...
bio-logo-footer.png
Blake Insomnia Therapeutics Inc. Closes Joint Venture with Sajo Consulting LLC
February 24, 2017 20:08 ET | Blake Insomnia Therapeutics, Inc.
NEW YORK, Feb. 25, 2017 (GLOBE NEWSWIRE) -- Blake Insomnia Therapeutics Inc. (OTCQB:BKIT) and Sajo Consulting LLC are pleased to announce completion of a joint venture agreement for the development...
bio-logo-footer.png
Blake Insomnia Therapeutics Inc. enters a joint development with Sajo Consulting LLC
February 08, 2017 16:54 ET | Blake Insomnia Therapeutics, Inc.
NEW YORK, Feb. 08, 2017 (GLOBE NEWSWIRE) -- Blake Insomnia Therapeutics Inc. (OTCQB:BKIT) and Sajo Consulting LLC are pleased to announce entry into a Letter of Intent to provide joint development...
bio-logo-footer.png
Blake Insomnia Therapeutics Inc. Seeks Financing for Clinical Trials
January 17, 2017 08:30 ET | Blake Insomnia Therapeutics, Inc.
NEW YORK, Jan. 17, 2017 (GLOBE NEWSWIRE) -- Blake Insomnia Therapeutics Inc. (OTC:BKIT) is preparing to launch a fundraising drive to complete Phase II clinical testing of its patent-pending ZLX-1...
Changes in Clocks and Amount of Light Affect Sleep and Health - Tips from a Sleep Physician to Successfully Deal with Fall's Time Change and Reduced Daylight Hours
November 01, 2016 17:33 ET | Centre for Sleep and Human Performance
CALGARY, AB--(Marketwired - November 01, 2016) - The clocks go back an hour at 02:00 AM Sunday morning, providing an extra hour of much needed sleep. "As many as 30 per cent of people in society are...
Pernix Therapeutics, Inc. logo
Pernix Therapeutics Announces Positive Phase IV Results of Silenor® vs. Zolpidem Head-to-Head Arousability Study
June 16, 2016 08:00 ET | Pernix Therapeutics Holdings, Inc.
Data demonstrated that Pernix Therapeutics’ Silenor® 6 mg was superior to zolpidem 10 mg on all measures evaluated. Study results presented at SLEEP 2016 international meeting MORRISTOWN, N.J.,...
Pernix Therapeutics, Inc. logo
Pernix Therapeutics Holdings, Inc. Announces Positive Interim Results From a Phase IV Study to Assess and Compare the Effects of Silenor 6 mg and zolpidem 10 mg on Balance, Cognitive Performance, and Arousability
November 12, 2015 11:15 ET | Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, today announced positive interim results from a Phase IV...
Global Sleep Aids Ma
Global Sleep Aids Market Will Reach US$80.8 Bn by 2020: Persistence Market Research
July 31, 2015 07:44 ET | Persistence Market Research
New York, July 31, 2015 (GLOBE NEWSWIRE) -- According to a new market report published by Persistence Market Research "Global Market Study on Sleep Aids: Sleep Apnea to Witness Highest Growth by...